Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant approved for extended use in both hospital and out-patient settings. The medication is an oral, once-daily factor Xa inhibitor. By directly inhibiting factor Xa, Bevyxxa reduces thrombin generation, thrombus formation, and thrombin-induced platelet aggregation, thus preventing blood clots.
LIST OF FIGURES
7 Figure 1: Bevyxxa for venous thromboembolism – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
LIST OF TABLES
5 Table 1: Bevyxxa drug profile
6 Table 2: Bevyxxa pivotal trial data in venous thromboembolism
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726